Mainstream media outlets love a good narrative of institutional decay. When reports circulate about political loyalists stepping into powerful regulatory chairs like the Food and Drug Administration, the lazy consensus immediately cries about captured agencies, compromised science, and impending public health disasters. Pundits clutch their pearls, assuming that political alignment with an administration equals a total abandonment of scientific rigor.
They have it entirely backward. Don't forget to check out our previous article on this related article.
The traditional view assumes the FDA is currently an apolitical citadel of pure, empirical science besieged by political actors. Anyone who has spent five minutes inside the beltway or watched the inner workings of drug development knows how absurd that fantasy is. The agency has never been apolitical. It is a massive, risk-averse bureaucracy driven by institutional self-preservation, inertia, and a pathological fear of Type I errors—approving something that harms—while completely ignoring the catastrophic human cost of Type II errors—delaying or blocking life-saving innovations that patients die waiting for.
Let us define terms. Regulatory capture does not happen when a politician installs a trusted ally to shake up a stagnant hierarchy. True regulatory capture happens when an agency becomes so cozy with the legacy incumbents it regulates that the barrier to entry becomes impossible for disruptive challengers. Big Pharma loves a slow, predictable FDA because multi-year approval timelines protect established portfolios from agile competitors. To read more about the context of this, The Guardian provides an informative breakdown.
When an outsider or a fierce administration ally is brought in to lead an embattled agency, the panic from the professional managerial class is not about protecting science. It is about protecting the status quo. I have watched companies burn through tens of millions of dollars navigating bureaucratic mazes not because the science was unsafe, but because career bureaucrats spent six months arguing over comma placements in safety protocols.
Imagine a scenario where an FDA commissioner actually views their mandate not as an authoritarian gatekeeper trying to find reasons to say no, but as an enabler of speed and modern medical reality. The current framework treats every new technology—mRNA, AI-driven diagnostics, personalized gene therapies—as a threat to be managed with 20th-century paperwork. That is not safety. That is stagnation wrapped in red tape.
The lazy narrative also ignores the checks and balances built into American institutions. A single leader cannot rewrite the laws of biology or bypass clinical trial standards overnight. What a disruptive leader can do is break the administrative bottlenecks that keep safe, effective treatments trapped in purgatory while patients deteriorate.
Critics point to past controversies as proof that political appointments ruin health agencies. They miss the broader picture. The agency's greatest failures historically have not stemmed from moving too fast under political pressure, but from moving too slowly out of bureaucratic cowardice. The opioid epidemic, the chronic backlog in medical device clearances, and the archaic clinical trial designs that exclude real-world patient populations are products of institutional paralysis, not executive overreach.
If you want better healthcare outcomes, stop romanticizing a dysfunctional bureaucracy just because its defenders wear white lab coats in press releases. Change at the top is the only shock to the system capable of forcing a bloated agency to modernize its review processes.
Do not mourn the disruption of the old guard. Celebrate the end of business as usual.
